<SEC-DOCUMENT>0001193125-12-499445.txt : 20121212
<SEC-HEADER>0001193125-12-499445.hdr.sgml : 20121212
<ACCEPTANCE-DATETIME>20121212091559
ACCESSION NUMBER:		0001193125-12-499445
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20121212
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20121212
DATE AS OF CHANGE:		20121212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		121257870

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d453848d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): December&nbsp;12, 2012 (December 12, 2012) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;8 &#151; Other Events </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;12, 2012, ARCA biopharma, Inc. announced
that the paper &#147;Effect of Bucindolol (Gencaro) on Heart Failure Outcomes and Heart Rate Response in Patients with Reduced Ejection Fraction Heart Failure and Atrial Fibrillation&#148; was published in the European Journal of Heart Failure
(<U>www.escardio.org/journals/european-journal-heart-failure</U>), a publication of the Heart Failure Association of the European Society of Cardiology. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated
herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Gencaro&#153; Cardiovascular Effect On Patients With Atrial Fibrillation Paper Published In European Journal Of Heart Failure&#148; dated December 12,
2012.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: December&nbsp;12, 2012 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">SVP and General Counsel</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEX TO EXHIBITS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Gencaro&#153; Cardiovascular Effect On Patients With Atrial Fibrillation Paper Published In European Journal Of Heart Failure&#148; dated December 12,
2012.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d453848dex991.htm
<DESCRIPTION>PRESS RELEASE DATED DECEMBER 12, 2012
<TEXT>
<HTML><HEAD>
<TITLE>Press Release dated December 12, 2012</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g453848img01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and General Counsel </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2100 </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px;padding-bottom:0px; " ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GENCARO<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> CARDIOVASCULAR EFFECT ON PATIENTS </FONT></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>WITH ATRIAL FIBRILLATION PAPER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PUBLISHED IN EUROPEAN JOURNAL OF HEART
FAILURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, December&nbsp;12, 2012</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing
genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, today announced that the paper &#147;Effect of Bucindolol (Gencaro) on Heart Failure Outcomes and Heart Rate Response in Patients with Reduced Ejection
Fraction Heart Failure and Atrial Fibrillation&#148; was published in the European Journal of Heart Failure (<U>www.escardio.org/journals/european-journal-heart-failure</U>), a publication of the Heart Failure Association of the European Society of
Cardiology. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The paper discusses post-hoc analyses of data from the Phase 3 clinical study of Gencaro in heart failure, known as the
Beta-Blocker Evaluation of Survival Trial (BEST), which was sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health, and the Cooperative Studies Program of the Department of Veterans Affairs. These data
demonstrate that patients with established atrial fibrillation (AF) in BEST who received Gencaro had improvements in heart failure clinical endpoints. Compared to placebo, the effects of Gencaro on improving heart failure clinical endpoints in the
303 patients in BEST with established AF were generally similar to the effects of Gencaro on these endpoints in the 2,176 patients in BEST with normal sinus rhythm. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The data also demonstrate that Gencaro made it more likely for patients with established AF to achieve ventricular rate control, and that Gencaro improved cardiovascular clinical endpoints for those AF
patients who did achieve rate control. 67% of AF patients who received Gencaro achieved ventricular response rate control, defined as a resting heart rate of less than or equal to 80 beats per minute without symptomatic bradycardia
(p&nbsp;&nbsp;&lt;&nbsp;&nbsp;0.005). In AF patients who achieved ventricular response rate control, Gencaro produced a 39% reduction (p&nbsp;&nbsp;=&nbsp;&nbsp;0.025) in cardiovascular mortality/cardiovascular hospitalizations. In addition, Gencaro
also improved cardiovascular clinical endpoints for those AF patients possessing the genotype which ARCA believes is most favorable for Gencaro response. In a substudy of 1,040 patients in BEST in which patient genotypes were analyzed, Gencaro was
associated with a 72% decrease (p&nbsp;&nbsp;=&nbsp;&nbsp;0.039) in cardiovascular mortality/cardiovascular hospitalizations in those 52 AF patients in the substudy with the beta-1 389 arginine homozygous genotype. ARCA believes that this genotype
predicts a favorable response to Gencaro, and is estimated to be present in about 50% of the population in the U.S. These data are in contrast to the data reported for studies of other beta-blockers, including carvedilol, in which AF patients with
the beta-1 389 arginine homozygous genotype who received those drugs exhibited evidence of resistance to heart rate reduction. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher O&#146;Connor, MD, Professor of Medicine and Cardiologist, Duke University
Medical Center, and a co-author of the paper commented, &#147;In placebo controlled trials of patients with heart failure and reduced left ventricular ejection fraction (HFREF) who also have permanent AF, currently approved beta blockers have not
shown benefit by improving clinical endpoints. In this study, Gencaro exhibited evidence of efficacy against clinical endpoints in patients with HFREF and AF. In addition, this efficacy appears to be pharmacogenetically enhanced in patients with the
beta-1 389 arginine homozygous genotype, and rate control was also effective in this genotype. This evidence of rate control by Gencaro in this genotype is important because it has been reported that other beta-blockers do not provide adequate rate
control in AF patients with this genotype.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Bristow, MD, PhD, President and CEO of ARCA biopharma and Professor of Medicine
(Cardiology) at the University of Colorado Anschutz Medical Campus, and a senior author of the paper added, &#147;These data from the BEST study suggest that Gencaro may be safe and effective in patients with permanent AF. ARCA would be able to
further test this hypothesis in its proposed trial of Gencaro in AF prevention.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA has been granted patents in the U.S., Europe, and
other jurisdictions for methods of identifying and treating patients with the beta-1 389 arginine homozygous genotype. The Company plans to conduct a Phase 3 clinical trial to evaluate Gencaro as a potential treatment for the prevention of AF in
patients with this genotype, subject to receiving the necessary funding. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product
candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an
investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the
potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with the Laboratory Corporation of America (LabCorp), under which LabCorp has developed a companion genetic test for Gencaro. For more
information please visit <U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release and the associated presentation may contain &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995.
These statements include, but are not limited to, statements regarding the ability of genetic variations to predict individual patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, and the potential for Gencaro to be
the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those
projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the
Company&#146;s business objectives and operational </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related
to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without
limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2011 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g453848img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g453848img01.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2@#;`P$1``(1`0,1`?_$`+L```("`@,!`0``````
M```````)!P@&"@,$!0(!`0$``@,``P$!````````````!@@%!PD#!`H!`A``
M`00!!`$"!`0"!P,-`````@$#!`4&`!$'"!(A$S$B%`E!414683)Q(S,D)1<8
M@34VD:%"<E,TU$5E5S@9"A$``@$#`@,%!`0)"P4```````$"$0,$!08A$@<Q
M05$3"&%Q@2*AL2,4D=$R0E)RLC,)P>%B@M)3D],D%19C<U0E%__:``P#`0`"
M$0,1`#\`W!.S'+$]R[+`J68<:%7M@MT;*H+DB<[N0Q7"]2`([/@2;;*OFN^N
M'W\1GU.:_F[OGT,V;DSQ]%P(Q>H2MM*=[(EQ5B3XN,;<.2:Y>5MW'5OA2PG2
MS:&-'!6X<Z"G?NM^4GV1BOSEXMNJ^!6>L9GRO$SG2O$D]$5]Y$1579-U0_SU
M2[ICTIW-NF<,W5<K,ABMIJ'FW4VO:W+O\#9N?DXV/6$(0YOU5^(SZ)4RQ:1W
MWYG@JJ/FCTA14T1%4?YU3R1%1?Z%U=_:_1J>%B0E;ED^4TU5W;C5?T>,NU=O
MN=>PB>1J5F4W%J'-X<J_$>I+Q^P8DK!-^9[_`)-"@JZ^FY.@#@)_-O\``TU+
MM3Z-Y,9O!E._*;<>'FW.-:-?G>T].SJV/.'G)0Y./<NZJ\#"+6LG,FYXS)0$
MBD.R27MO,?3T13^"DFVJJ=2>A.H6XW;^D9.99R4V_P![=I7P?S=A)<#4K$TN
M>$))K]%?B.?C[DN^XYR:-8M3'G8)O-,7$-_S>9E0%<1']D)?-'F052;4538T
M3?=/36G^BG7+J)Z:^IMC65D7Y:2[T+>=8N.5R%_%YOM.7F=5.,7*=IQ:2FH\
MRDJI^;<6V=-W1I4L:4(J_P`K=N2HG&=.'LHWP=>ZM*=HURKL(]M6P+2*2%&L
M(D>8RNZ+_5R&A=%%5/3R%"V7^*:^G;;FNX6Y]OX6X].=<'.Q;5^'&M(W81FD
MZ=Z4J/VIE0\K&N8>3<Q+W[VW-Q?OBZ'>UFCUPT`NK[AO;"VZV87B,/#9C3.;
M95D,%U!4&W7HN-5CKDVRDBVXA"3<XH/T:^B[(^JHJ*B+H"YW$7(-?RIQGA/(
M%:XVXSE&.U=F\C7H#$]Z(TME$1-R5%B3T<;5-_B.@)'T!&O*O^:Z8L9\-GAJ
M9>W+:(6LYAV4RFD0?!U'FA&KM*E]F4KJ@HF3B@@HJ**JJ*@"@.:_N"]O>MN9
M_LSESC?B09DN$<^FE4#&1.PK&&A-(DMN2YDKS9"'O"CC:?,V2[*NZ:`L#PKS
M3]P7G##8'(-+A?`6.8M=LO2:%R]B96MC/C@YXLNG!#+F7&&)`_,VZNXF&Q(F
MRZ`POD/O1V:ZQ9)3P>S/#6(R\;O'G4@7_&LNR;B/,-$@FGU5E/MHX3@$T/Z=
M?G(1+;\]`,KX>Y@P;G+!:CD'C^U"SH[5I%4541F5\L41)-=81T)3C38CJ*!@
M6RH0KZ:`E'0"\^S7W#^,N"+I_C_&:^5R5R@+_P!">/T;H+!J9YJK8Q[.<VCP
ME.:?3Q.(/@]\?5-M`8WB;7W#N:J\;^WO>/NO%3/8)^JK/VW9762!&>4"9&UK
MY=PAP;`&_BAHB(JKN/PT!RYAQU]PK!($ZZPKFG#>5S9(Y#>.7.,?H,M(T8#-
M&6Y3<[VI3TA%V4105)13;;\0(WZ9]YN:^9.>)_!G+^*XQCME4X_?S9+4&ENZ
MN^CV5`<-N1%LAL+B5':-/JDW'V`)=OPT`W/0!H!:_P!P?N)<=9XG'-1AA,/Y
M/D%VEQ;1R0#-O&J9^*X[$<$M_;;OO)YE#VW'VU5%30%_L'RRKSK$,<S"DDMS
M*O(JF)9PY+2H3;@2&T4O%4545!=0A_V:`RK0!H!2_,FSO-6>@9?*W=@O@NWK
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M9H@_6*U\S,8BV48P*F_NNHBHI%Z)N7CMNFZUTZA['Q=/M/`X7M2:^?E?RP;[
M()]\NQM\.WEI55)UHFJ3ROMU\N-^;7M=._V+P7Q*X97$.,I_U9`Z(KY>0>"[
M(JKZHOPW'X?GKEGZC.GRM6;F=;AR95A-M<M&U2K^AU?X3:^A92NT3=8,:IP^
MOEQIAZ[JN]2WZJNZ_P!J[KNQZ7N;_P"`[6YZ\W^V0[?UI%5-YJFZ,Q+^^?U(
MDG6^R,'X1"`D9*@B(J1$J[((BFZJJ_@B(F@-:SM[5Y%V\N.SO/>/R9,C!NM,
MFIXUQ&J`E)VPLX]MC\++G`$$47X34J7-E(0[**"FZ[)H"V_V<.=6LSXMROA^
M?+4K3C^P=MZ2.;R...8Y<21DRY`BNQ`VQ;V2-I\4]=`.=T`:`UKOO3600^:N
M+VU^*X%<K^/I_B-;\-ET`ZSI0Z+W57@MT4V0^.<6+T3;XT\/0%:_NTP*9_J;
M8V-F+22Z?+J2;3.$0`Y^H+"MXZ--DJ*1H<=YQ5%%3?QW_#0%5/LEY!=V%7SI
M6$LES'HECA[['F)E%B3WXUX1`R:KX-G*3S(DV524-_PT!<[[D7:^1UHX;;A8
MQ(1GD/D-Z528Z\AB#M3`",Y^IW[0[^3IP77&&T'T]7M]TVT!1/[2G7*#GC]Y
MV=Y`B_KCL.XDU.#+9H4GRNH[KB7E\\KRJKDV&X#8,DJJFSQ[IOLJ`;`6@#0%
M.<UZRN3>T_&/8S#'*RHE5%1=X_R(P;?MR+ZMEN5AUCD;VE;'ZA@6I*.J:$I^
M8_#;U`N-H#C==;8:<>>,6VF@)QQPUV$`%%4B)5]$$43UT!J\=JJO)NT]-V![
MAUDB5/P;C;-*3C#`(K(&@R<7J),B=D=E*1%<`AJF[@7/(?'9#^;?TT`R?[1G
M.[')'`4GC6;)]R_XGL5@,,*?DK>(V+;14CA;DI^1V#4U-_ALB:`;)H`T`H_E
MMQ?\[^0T1P!\<E9V5Q=FP,JVM]37UV3X;ZX2=1;-J?JKWNITCSZY"+;X</NN
M-VON7'MXT+:[73_X+IKHW_IGV?KS)TXI%]GV1')<4;A/NI[]99SE<&41>(^L
M1&@(R7X(J&GPU??H_C7[%BW'[_IRQ)22E9N7.92;HOR*)U_K&NMTRA-R;Q\E
MWDN$X1I3^M5_48I:Y2-CR3;A(]MB+`D,P8,5DE^DBQ0;;,FHP+OX-&\X9_TF
MNM=Z/O>WN7J5J5W-E;5O'R/)MVHOY+4(1BZ03?!.3E+WR9E[>EO%V[9=JKG<
MAS2D_P`J4JM5?MHDO@65CW>/!CR*!B,H!0@=`A\A44$D45_!1+UWU;RQJ^C0
MT=.VTKRC5--55/JH^\UK/#SWG4:^S;XHQW*Y;D['8,N!<8Q0C807');$F0L.
MTEN#)?CD;AD+R.@;;2+\$_'47W5D2S=`M9.%E:?B1OVI.:E+R[LWS2AQ?S<R
M:7@C(:9:C9U"=N]:R+TK<THM+FA'@GP7"CJ_$HSFRC')QKZJ-(54<\SCN^\&
MY>:"BGL/J:^J?FBIKE_U^Q(1T_*MRG:NQE:DGR2YJ4JZ]B^!O?;M9TERRC1K
MM5/`:;PV7EQCAJ[[_P"$AZ_T/.I_S;:ZO^F=*/0G;<8]BT]?MS*Q[TX;HS?^
M[_(B3=;U(N4S[[<_PNNW6CD++4)',CNJIS$L0KQ<1N1.N\C<9I]XQ;[^]7Q)
MSDE-D7^Q_#XH!%/3[`>-L$Z<8WQ=E&9XP]>\@X?:W&;3)%G#*8_;<AMS;=TI
MPN."13:MFY!I=_5#9^.@$&].^3&^H??X,0FV"?M*1F=[Q;9RV)`JW:4$Z?-A
M8C+1S?VC"79#`>_BB^BZ`W%-`&@-7'[Z%DD3G?B9I41//CV[7=?7_P`TJT^'
MX;;Z`MYUX^Y]P7P9UAXAH^0\'YO@/T.%T5(MO#X^25C%I*A5C++;U;>%;L-N
MQ98L^8FK:;"OX_B!"7(?,G(OW@<BB\/<(0:KCGB3CVV@Y/EUCF-N3N16SRM2
M(4&UAT4:)'0@KX\]YM6%?7R)Y"]Q/'8@':=8>M."=6>,:WCG"`<E$/C+R#()
M3;86&0W!JXY(G24;W]IE'7W/9:4C]ELO'R+XJ!KT_?`S::[V&P7&9'O_`$.-
MX.Y(@(XBI'4[PZ^1+5CUV)4.(/G^2JF@';_;8JJZKZ8<(G6LJR-OBL&]F(I(
M7N6-I$C/S'DV$?%''/79=U3\UT!>K0!H`T`:`7Y]RWG].!NL&6.5DE0S/D03
MX_Q"-'-$L?K;YDX4BUA!Y`1?HXR6W#)%^7S'0''PUQ1Q#C73BMZXY#F6)&N2
M<?3:;,IS5C"%9MSDM8L>RM2;-Y5^J0'`3=5WW;3UT`@?[;W,KO77N[&X^R*4
MQ%I\RNY/&5L#4I%BNVDN8<3$W4?_`+,VVI5BAK\NZ^2HFWQT!M_HJ*B*B[HO
MJBIZHJ+\%1=`&@$L\Y6GTG/?);1$@BN1-E\/E^2JK5'=-_555=?/KUDU]:7Z
MMM[X]QI1EJT&OCC8Z?\`.7.V7B>=L#3))<?N[_;F27QEF,"#)A!#IF[FY==9
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MDO(TCD6(@M@XKP[JBJX/BB[_`,-2C:FV.JN;S+=UM:5I6/&,K[G)N]Y4G2MN
MVDE)OQ<XT7'CV'CU#6-O0DO]IKDY=QM6Z*D.9*M)2XTI[GX&3<F9?60HL2M?
MKZVSI1@-A0756?Z?).(@J']Y>]N2IN-RQ<4PV3<M_7UWU..I&[-,T[`MX%ZQ
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M(_HB:`U^_N[]2\9Z=\E<99QPQ5/4."Y3#`VFR=)X:G.*-\94-IDT;:0AD1ZX
MI*^J%Y;I_'0&S#T-Y]K^R75?B;DJ(YYSCQR+C60(;HN/+D>)@./74ET452:^
MNL*YQX17=?$T]5^.@+@Z`U*O_P!`=HD'L'PZ";[GQK?*OP_"UJ?S7\ET`\3J
MAQCAO-_V[N&N/,XJ(=MCN7\*8I7SX\N,T\@&Y0U[C$H$)/[:)*`'07=%\A30
M&KQ8V7*_VI>\1Q0D394/%K4FFY)H['A\@\7V\E%966W[BB9R(C;$EQKR<1J0
MV*>2_'0&Z?Q#ROAG-_'&)\I<?V86N*YC3PKBM?0@5Y@9D=I\X,X&S<!BP@DY
M[;[:$7@X*INOQT!KI?\`Z`N+;FNM>&N<*Z%)>Q]YBYPG)9J"I,0[A_\`3Y>.
ML;IZ"DN%7S"7?\6_XZ`8#]ESG6KY;Z>4>+_5@N2\2V3N(VU:KHF]%IQ0V\:E
MJGHHMSXL%U43;Y?!4W70#==`&@(XY7Y<X[X0PNPY!Y1RBNQ'$JQQAB5;V1J#
M/U,I2&-%;04(G)$@A5`%/5530$ALO-R&6GVB\VGVFWFC3X$VX*&!)_UA)%T!
MK^<_QJGO_P#<RQ?K?-61<<*]:<>L+CD)ILO[I^])DAHK6A>4/<;#]4@UT9L#
M7=5\"]/30%Z/_JAZ3?\`MB[_`++0O_#Z`US_`+J_6JNZ4=A,+R#A^-+Q_",F
MJ*^_Q5U"4BJ,SII\YRPBQGT0!((<=J&\*HJ%NXJ*GINH&V+U,YLJNP_7?BKE
MRI\`;RO%H+TN*CXR'8=C$0H,QB08HGB^KL?W%14140TT!8K0".>V599XSSQE
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M?;LM4O0N.::7>IN5/<U1/V%>;[D)QUAZ&W*4XA/^Z+3AJJ"YN(@ZVGJC3AB`
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MLT'+L\JY_*5'4.%1\752.S\IM+R;$;<IH[D0`%B+#4I33[[CKH*,5"(4,O$"
MVD8`1K]ESMQP4?+_`&:Y2Y^S^EPKG'F3+7#HDR8Y;'ZAB$Z1$N@I:ZP=B^VK
M=79@K8-D0)X-)LGX:`VN84R+8PXEA!?;E0IT9B9#DLEYLR8LIH'X[[1)Z$V\
MR:$*_BBZ`U]?OG\V=7\SZMWW'KW*&,V7-N%YC5W&$X/`.5,OBOHTTZ&^;,6(
MIMP?HZ29,4R,QW4-DWWT`L?[+_W+N/\`JO/S'AGGR?.QWC;-[&->8_F;\>7)
MK<4OVP;C.P[5I&T=BTU@V;KA/-"Z:2%!/;V)20#;-8[3]=Y/&8\R,<NX:YQ<
M3_THYLEB24BR?!YSZ?WB:1SW_!@U\?#R^5?30&FY][/MCP_V9[%85/X,RA,\
MQO!\)G4-AE%5%FA23K*RE5LU6:QYZ,T_)&$L<VW2)L$]Q/E4A]=`/F^UU]Q/
MJI>]8>%.)+WE*DPKE+#\8IL)L,*RI9-=:RY=,S&IF)\!Q6#AR(=JXT)LK[B.
M*AIY"*Z`S'[QW1P^U'`#V>X)6H_S-PVQ,O<>".R)3,EQE6B._P`51SY5:)\F
MV98N*I>/TBB@KY>@"%OM#_=0K^IMO:<.\XR[X^#\EEE+JK)F/(G)QYDAR'#E
MOO1'E:*+461272F>WNZ+K;?]67JJ`;3-[;=3/N1<'YMQQC>>8YRGA-]7"Q-L
M,:>?&RQR=*8?&MN(938D:;56;*$?MGX`?BICZ;KH#6#K<6[?_9'[,R\O_:MQ
MR;P%D,E*>VNZEF4N.YWBZR!?CG)CL-3'<?S*H8;W1PFG6F$=<;%TA-5T!L[=
M;?N*=2NTM#"M...5J*)</,-N66&97+C4&4T,@Q4B@VL60^4$93:BJ*C,AT=T
M]%T!)W+_`'`ZS<$4$G).4N:<#QBLCL$]Y'=QK&0\J"9`TS%JEFODZ\K:H***
M)O\`%43UT!K&\R]_,C^YKW<ZY<"\>X]D57UEA<R8P;[4ZNE"]E:,V;/O97DC
M<8'H#42O9;%8K)/.HRCKBH7SKH![O<O[E_7'J'@V9P7LXILFYDQVOE5N/\65
M2OR[J5D4>+M&C6B-L%'KH3+OA[QD2F(DGB!>J(`H;['79[@"DD=@,MYGY1J<
M<Y^Y?SJ%)EQ\K<FLRKNAB%/>J'*^8]&-IQP)-B\VZ*F)*B!MO^`&T\!@Z`.-
MDAMN`)@2?`@-$(23^"HN^@-:;[\_.?5[D;KY2XOC_*6-9+SG@F>5TG&L/I3D
MS[5FNMYL&#F+\AUB,;$((M9!120C\C4=MOR`JI]ES[H?&?7O&[SKEV(N)&'X
M=89!(RC!\_L8\N13U4ZQBPH-C07;HM+)KX'A6,N12;!X5===\D!/F4#9M_UE
M]6OI/K_\\L"^C_9/^9'U'ZJ7M_L;];_;?[EW]C_=_P"N_P!UW_G]WT\=`9)S
MEP%B/.=&U7W9'5W$!'%I\BB,`],@$XB>0FV1LI*CJH[^V1H/Q_-=5W]0GIMV
M/ZAMOPTW<5<77,92^[9MN*=VRY=J:K'S(55>24J=OBR<[(W[JVQ\UW\*EW#N
M4\RU)TC*G?6CY7[4JBS[K[?W-L":X%-<X?:P?<7Z>25A/B22;$OE65'6K5ML
MR3XB)F/\=<KM6_AL]<]'U*3V[GZ-DX/,^2?GWK=QQ79YD/(Y4WX1E)>TLCA]
M>]EY%E/,LY=J_3BN6,HU_HOGJU[6E[CJ-=&^Q#(["_B"^OHJW$S=$^.W^[/P
M766PO0SZF<6+B[FC.O?]ZN_Y!^W.M/3Z;KRY?^''^V<J](.Q)?SO8@2?!?\`
M&9J*J?EO^F>FO;N^B/U-W(.*N:-6G_E7?\@\:ZS=/DZTR_\`#C_;.G_H.[!2
M'!$W\,;1PT%7'+>;[;:$2)YGX51GX`B[KLBKM\$U$LO^'GZD-4NJ&5>T11E)
M<7DWJ*O>Z8[=%VNB;]C/;77/8-J-8QS'1=UN-7[OG[2XO7SI55<9V\3,,[LH
MN49/7N"]50XC;B4U7)$4VEBKPLG.?;-55M3:'VR%"3U3TN=Z:_0+M_I-KMG?
M._\`)M:ONS%DI8]J";Q<>XE^]7.HN[.+=;;G;CY<E&<?F2IJ+?\`UGR]RXD]
M(T.W+%TRXJ3E)KS)K]'A7E3[Z2?,FT^!?+71<T40#DG5/K+F.87?(.6<`</9
M+G62C$#(<PO..\5M,ENP@18T&$-K=3*MZPGC$APVFFT=<+P;:$4V04T!C\_I
M7T^MA::LNL7`EB,.0W*9;E\5X5)2-*;\7&GVQ=IS]IX-D42394]%T!9.OKX-
M3`A5=9#C5];6Q(U?7P(;+<:'!@PV0CQ(<6.T(-,1HT=L0`!1!$11$39-`5[L
M.GG5"VR6YS*SZW<(6&6Y&^])O\EF<8X?)O+J1(>^H??M+1VI*9.=>?\`G(G#
M)2+U7UT!\/=-^IDAIQA_K7P<\R\!-NM.\88<;;C9)L0&!5"B0DB[*B^BZ`]`
M>IW6`>/EXG'KWPT/&"VOZZO'J<<XHF&K=;/C^JKCGZ7^E?J'C*<3WO:\]G"]
M?5=`><QTVZEQ6&8L;K5P:Q&C--L1V&>+\.;:99:!`:::;&H00;;`41$1-D1-
M`=63THZ?S)E=8R^L'`LF?3R69E5-?XJPIV572X[P2&),)\Z97(S[,AL3$@5%
M$A14]4T!9EX&G&S:?%LVGA)DVW4%0=%P5$FR$O0T,55%3\4T!7%.G'4T7YLH
M>M?!R2;*;)L;!].,,.1V;/F.D_+FRG$J/)^5)>-3,R52(E557?0&=<;<$<*<
M.2KZ;Q-Q-QWQM,REV,]DDK!\0HL8?OGH:.C$=MW:>#$.P<C(^:`KJDH^:[?%
M=`2/;5%5?5LVFNZZ%;U-BP<6?6V,9F9!FQG/0V)45\'&7VC3XB2*BZ`H;G7V
MLN@_(-HEQ<=:>,Z^8ON*ZN-8U4XXQ*<=42-Z5'JH<=J0^JC_`#DBKZK^>@.G
MB7VH_M_8=/\`U&#UEXTM7=P5&<FQRKR*&BAOMM#M(<B/ZJOK\OKLF^@+A83P
MKQ#QJK9<>\8X'A"M"H-+BN*TM$K8DB(0@M;#C^*$@IOM\=M`8/;]2NKN09+D
M.9WG7CABWR[+9OZEE&367&^)S;W(;#94^MN;615.3;*5LJ_.Z9E_'0'F2.E_
M466[#?E=9>"9#U=*;FP'7N+<,<<AS&20FI48SIU)E]LA11(=E14T!95ML&@!
MIL!;;;`6VVP%!``!$$`$4V01$4V1$^":`K0'2WJ&W9VMTWUCX("WO'UDW-F/
M%F&#/M9"F3BOV$I*?WI;JF2KY&I+NN@.:1TVZERV'XLKK3P;(C26G&)$=[B_
M#G&7V714'6G6SJ%!QMP%5%145%1=`=3_`$3=/?I?H?\`2]P']%^VOV;]+_E3
MA7T_[2_6?W%^VO:_1O#]#_7O[Y]+M[/U/]9X^?KH"S^@#0!H`T`:`-`&@*]=
MJ\]<XRX"Y'S6/D[^(3J:F%VLNXL*)8R&K-^9&C5\5N',,&7$L);P,&6_DT#B
MF*;BF@(]Z/UF;1.$*+(.3\EM;[D#D)7LUMF[JXE64J)!G.FS3A#9FO..0Z\Z
MEM@Q;;$6A4O1-`6VMQE'4V8093,&:=?-"'-D;>Q$EE&<&/*>\D(?:8>42+=%
M]$T!"/7G%N9<5Q>XC\T9Y0Y_<3K^;84=GCZ2"B1J*0ZZY$C&[)@0#<<\#%=A
M$FP_E`E%$T!.SLR(P\Q&>E1F9$E52,PZ^TV](44521AHR0W51$55\47T30'9
MT!"=3V!XUN^7\EX2K[CW,VQ*FC7=TV:-LUT>/*.$VW&;FNN@#\]#G@A,@BFF
MQ;I\JZ`FS0"LSR7D#/ON$/\`'\+D;(9/&_%-&&>WE5&DE44#4MYIJ"E#/&#)
M!NT2$]:_-]4/\S>_K\=`-&8D,2F@?C/LR&'$\FWF'`>:-%_$'&R("3^A=`<V
M@.JS.A2'GH[$N*](C%XR&&9#3CT<O7Y7F@,C:+T7T)$T!R'(CMNM,./LMO/^
M:L,FZ`NO(WX^XK39$AN>'DF^R+MNF^@!F1'D>Y[#[+_LNDR][+H.>T\'H;3G
M@1>#H+\1794T`%)C@\U&-]D)#XF;+!.@+SP->/N$TTI(;@M^2>2HBHFZ;Z`X
MPG0G/J/;F13^D(AE^$AHOI2%%4AD>)K[)"B;JA;;:`Y&)#$IH'XS[,EAQ/)M
MYAP'FG$^&X.-D0$F_P"2Z`YM`=5J="D/R(K$R*])BJ*2H[4AIQ^,I[^*2&0,
MG&5+;T\D3?0':T`:`-`&@#0!H`T`:`-`)S^Y3E65<J<@<*=1N,!&?E&6W+&8
M9(R0^]5M4U8<DFH]_L+B,18CD09A"0JK@"B(A*J"H'B\5<<YCA7?WCO#\;Y2
MS//8>"<7OS.<4FVU@[B]983*&QKL>QRHKD?6NAUD%9D!QACVVC%!$U!"W70$
MH_<_S+D"FPW$,+P[,GZ-_DFWK<4Q_'L8EV,/,+_*9EF*F4Z77`W(@8A#I6W7
M''&GD(Y#:-F*MD6@+4,W7^DWJ4S>YU:R+F;QAQW!?N9EC*<DE*R%R/%BM03E
MFX;CD5;V8$<#WW]O94T`JK/+G.7.G^7=O>5,PRICFWDR[I!X5IZK([BIJ<(8
M_<\2355%14U\V)6/N6V/P#)QTF3>>:,D-5\S30#@V,NR8.LE1G-Q=M8MEY</
M4&36]U,BQ'@J\@=Q:!8V3CD*2T<,W?KS<`6R!1\R1-M`(4I^.AN.E7//=+,<
MBRS_`#7R;)3MN.,IC7]OB]@:Q\M9J91/4E%-AUCZ60FZ\#1M&VVB)[6PHF@'
ME\#9S<Q.IG''(.?V#ZVD?A^AR*VL[EU$E2"#&8TMN58//$IN2Y:^*F3J^X;A
M?-\RKH!2?4;C'->QL#L7V&S;*\CP?B[/\@R'*&UIK"3CE_DCT)+A\((WD)V%
M9UV,5Y/KYL-/MLONBU\AHFX@7?\`M;VF5RNJT?(<PN;R?3R,CRB9CLG)GWI%
M@SC\6QF$DDY,HW7RA.QT`VD\U;$!^38=`=#..Q`<I8AR1RY*S"TX\ZN<;E<4
MT&QI9GZ/E_,F45KCD9[]"LXS\>YK*..\P7TY0WV9$H'$/P)`51`];[:/'^5U
MG#%ERUF]MD%GD_,]B&3Q!R*XMKAV)C8C)=Q\Q?MGY$D79K%@I/+\241W5=`4
MCY=9YQY-^X54<6X/REDJWE(P5YD%Y1V5E'Q/`Z"7(!M:N-2@K-;(ET7A[;I/
MQ_=FJZ*FKBMHH@-?ZZ=9VNNQ9^</D_/N06LWL(=DVQG=J_:!0/0TL%)(#TB3
M)>,II3D^H=-5<=]H/)5V30"@2G\W\Q=VLIB5',MM6T7%55*:YCS^ILI;>$8:
MPTX\>056'P'_`&:U6U9B_P!RE&PT\^H%[A)X#H"%\'R/*O\`+_M!S=)Y'Y(Q
MWKH_<N4V'5,G,,@?R3D#,V1G_H5)`NY=D=Y'A@;CBSW@D![POM)NX@(@@.VZ
M%X5F?'/6+#V>2[>S>O+=9N6R6LBL94J7CM=:,Q/IJ>3*L73)IJ$W%5S9#5L?
M=5=_5=`0UF78QCE;%N1>6)64W''_`%4XO.RK"N::8Y0Y?S/D=<R4F1!Q^R9>
MAW=)2DT3#4-Z,]&D27WG15%]L50#TOMH\?Y+!XAL^8\VM<@M,CYDN)-[7K?W
M5I;RH^&,$(8\U(6TD/OMSO<60KBE\Q"H[JOIH!DN@#0!H`T`:`-`&@#0!H!7
MV7=5>RM7V]Y([#<499QBD'D?&*?&:]_-VKN5:\<LPJVJ@S[#'H<2'(@R;"6M
M>ZH@\+K"H_\`.GQT!<'@'KYC7!%)<)%G3LHS?,;1_(>0,]NS]^[RF^EDINNN
M'LC<*MB!XLQHK(MLM,M`B"BIH"HG/O37FKG#MCBW+2\F4>-<8X?CR4U%%C1Y
M$C+:=N;")J]6KCOPGZ9;&TDRI(#*=W=C1WE)DP>!M1`MKSUP'7<T=<LOX`.T
MEQ8=]B%9CL&VGRI,V6$F@>K)M/+LICQ/S)AG.J&2D.$1NN(I*JJ2Z`I]7=,.
M7.4+/@^B["7^$1^(.OU'C$>@P+`BME+-\MQ>HB5</)LG?GL@C#`^VXXC;#@*
M1$B&"HI;@=C[IO)TO%>`:OAW$G!;S#G;*\?XYJHD0"21!J9;YRY%HT#([M0X
MCM6VTYXINC9JB)MH#S:3I5RWG&$\-\*<QW6"T?"'#[-3+L,=X]=NOU?DS(J.
M(L2OF7\J>R(Q:AQQQR0\RTXU[CZCN"HGH!</LWQ#E?+G`>6\.\:V^/87,R>N
MK:%JQLX\P*ZHHXTV&_)9@1ZIATVGEBPT9:%`]L1)4]/30%7IO5;L5'K*+@/$
M^1<*Q?J['XWP_#;QB%6&/(3MA50J\<JM:R;^F&W]5D%A#)45UU!1EX]]C\=`
M6XSCA[RZ^WO"O$\B-@^V#IA^(2A)\6*=J/&8AQ3>>:1R4ZJQF?%QQ?)PU)5)
M55570"DLO^VGVKS/KYQSQ1<<S8,KG'M_7K2XK7P),#$&*)MB0$J=:.QZIB?;
MY!Y`R@DZKH()N;+Z^H#>N#^*IW$7'47%)60R,@NU%R5,FO./)4PIS[*;5M!`
M46VJS'JYW<(S+;3?BULBCOZ(!!_53JSD/"V:<Y\J\D9%0Y?R3S5FCM]*L*-B
M<-?24;3\]^'4P"M&&9;"NE8*KX`B,JK0;?#0%L\TBY/.Q/(8>%S:RMRR54S&
M,?GW+;[M5#M'62"+(GM1FW7SC-.+N2`)$J?AH!94#H)R=A_3_(N!<!Y#PZ#R
MER=>+8\N<D6L:[<8OJV?YI;U-?)9AN7)LH#IC&5]$5OS+U3==`?/8'H+GF88
MEUGXHX=R;#\:XPX<EN3LJK<B@OR#R.R:2K^DMI3#,*2U92Q*,\N[WDI>7S;Z
M`NKD?"UR/7',.&<1R^T7)KK!+W&ZO-,BG2ILUN\M*QV%'MI+A$^3#,=TA5&F
MA0`$?E'X[@*FRC[:O:?,NN>$\-WG,6$F&#V\4:3%HK-C!Q$JP7F7)5K?2H=<
MQ:VUV]X[)[A.MLH`JUXD1JH#?.".*I?$&`PL7L\CEY3=./?J%S:/?U$!;!R%
M"AN1Z.J:!B#2TS3<$?:C1V66D)2/P0C)5`F;0!H`T`:`-`&@#0!H`T`:`-`&
M@#0!H!-W>O\`^=?1O_A_^VO?^*/]V?SV7_=O_4_^ST`Y'0!H`T`:`-`&@#0!
/H`T`:`-`&@#0!H`T!__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
